Singapore, April 21 -- South Korea-based DAAN Biotherapeutics, a leading innovative drug development company specialising in T-Cellreceptor (TCR)-based therapies, has signed an exclusive licensing agreement with GC Cell, a gene and cell therapy firm, for the tumour antigen-specific antibody sequence.

The agreement grants GC Cell exclusive rights to utilise DAAN Biotherapeutics' antibody sequence in the research and development of CAR-T (chimeric antigen receptor T cell) and CAR-NK (chimeric antigen receptor natural killer cell) therapies.

The antibody at the centre of the agreement targets a tumour antigen that is highly overexpressed in major solid cancers, including lung and colorectal cancers, and this antigen has continually been us...